Hiroaki Yanagimoto

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2013 · 633 citations

Medicine, Oncology, Pharmacology +13

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 334 citations

Medicine, Oncology, Chemotherapy +7

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 232 citations

Medicine, Oncology, Surgery +11

Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study

Susumu Hijioka, Waki Hosoda, Keitaro Matsuo et al. · Clinical Cancer Research · 2017 · 188 citations

Medicine, Oncology, Chemotherapy +16

Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis

Sohei Satoi, Tsutomu Fujii, Hiroaki Yanagimoto et al. · Annals of Surgery · 2016 · 111 citations · Full text

Medicine, Oncology, Pharmacology +16